Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Multiomics and proteomic insights into Alzheimer's disease biology in Down syndrome.

Expert review of neurotherapeutics·2026
Same author

Corrigendum to 'Role of CD40 in prion disease and the immune response to recombinant PrP' [Journal of Neuroimmunology 257 (2013) 21-27/475655].

Journal of neuroimmunology·2026
Same author

Interconnected influences of diet, gut microbiome, and metabolome on cognition across three metabolomics platforms.

Research square·2026
Same author

Short T1 Fraction as a Marker of Myelin Content: Evidence from Postmortem MRI and Histology.

bioRxiv : the preprint server for biology·2026
Same author

Amygdala microstructural changes in subjective cognitive decline: A diffusion kurtosis and neurite orientation dispersion and density imaging study.

Journal of Alzheimer's disease : JAD·2026
Same author

Neocortical tau burden determines the degree of cognitive impairment in individuals with Braak stage V neurofibrillary degeneration.

Acta neuropathologica·2026

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Desarrollo de Fármacos

Noor Salaymeh1, Akash G Patel1, Pramod N Nehete2

  • 1NYU Grossman School of Medicine, New York, NY, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
Resumen
Este resumen es generado por máquina.

Este estudio demuestra que CpG-ODN 1018 es un enfoque inmunomodulador seguro para tratar el envejecimiento cerebral y la patología relacionada con la demencia, como la angiopatía amiloide cerebral (CAA), en primates no humanos (PNH). La investigación futura validará su aplicación clínica.

Palabras clave:
inmunomodulaciónenvejecimiento cerebralangiopatía amiloide cerebralprimates no humanosdemenciaCpG-ODN 1018seguridadeficacianeurocienciainmunología

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Área de la Ciencia:

  • Neurociencia
  • Inmunología
  • Gerontología

Sus antecedentes:

  • Los primates no humanos (PNH) son modelos cruciales para la investigación del envejecimiento cerebral, particularmente para afecciones que no están bien representadas en roedores.
  • Se demostró previamente que los monos ardilla (SQMs) con patología esporádica relacionada con la enfermedad de Alzheimer (EA) y angiopatía amiloide cerebral (CAA) se beneficiaban del agonista TLR9 CpG-ODN 2006.
  • CpG-ODN 1018, con un sólido historial de seguridad en ensayos clínicos, fue seleccionado para evaluar su eficacia y seguridad en la mejora de la patología relacionada con la demencia.

Objetivo del estudio:

  • Evaluar los patrones inmunostimulatorios de CpG-ODN 1018 en un modelo de primate no humano (PNH).
  • Monitorizar la progresión de la enfermedad utilizando medidas conductuales y biomarcadores de fluidos/imagen.
  • Evaluar la seguridad y eficacia de CpG-ODN 1018 en la mejora de la patología relacionada con la EA, específicamente la CAA.

Principales métodos:

  • Monos ardilla (SQMs) geriátricos recibieron inyecciones de CpG-ODN o solución salina cada 5 semanas.
  • La respuesta inmune se analizó utilizando el sistema Nanostring nCounter.
  • Los biomarcadores en plasma y LCR (patogénesis de la EA, neurodegeneración, neuroinflamación) se midieron utilizando SIMOA y Luminex.
  • La función cognitiva se evaluó utilizando un sistema de pruebas cognitivas automatizadas (ACTS) basado en pantalla táctil.

Principales resultados:

  • La administración de CpG-ODN aumentó la expresión de genes inducibles por IFN y citoquinas-quimiocinas (p. ej., IFIT2, Mx2/MxB, GBP1, MIG, IP10, MCP1).
  • Los análisis preliminares de biomarcadores (Ab40, Ab42, NfL, GFAP, etc.) no mostraron diferencias significativas entre grupos ni a lo largo del tiempo.
  • ACTS demostró potencial para el monitoreo cognitivo longitudinal en monos ardilla (SQMs); no se observaron anomalías de imagen relacionadas con amiloide (ARIA), lo que confirma la seguridad.

Conclusiones:

  • CpG-ODN 1018 demostró efectos inmunostimulatorios y fue seguro en PNH, sin ARIA observadas.
  • El estudio apoya el concepto de inmunomodulación como una estrategia terapéutica segura para la patología relacionada con la demencia, particularmente la CAA.
  • Se justifica una mayor validación de CpG-ODN 1018 para su posible aplicación clínica en el tratamiento de la demencia.